March 24, 2026, News Release. Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II Cardiac Surgery-Associated AKI Trial

🚨 Arch announced @fraserhealth.ca has entered into a Clinical Trial Agreement with the Company to enable Royal Columbian Hospital to prepare for recruitment in the Phase II CS-AKI trial evaluating LSALT peptide.

📖 www.archbiopartners.com/investor-hub...

#AKI #CSAKI #NephSky

March 20, 2026 - News Release: Arch Biopartners Announces St. Michael’s Hospital Commences Patient Dosing in the Phase II CS-AKI Trial of LSALT Peptide

🚨 Arch Biopartners: St. Michael’s Hospital (Unity Health Toronto) has commenced patient dosing in the Phase II CS-AKI trial of LSALT peptide.

🧪 News also provides ongoing Phase II clinical trials updates.

📖 Full release: www.archbiopartners.com/investor-hub...

#AKI #CSAKI #NephSky

December 16 2025, News Release: Arch Biopartners Announces Ethics Approval for St. Michael’s Hospital to Participate in the Phase II Cardiac Surgery-Associated AKI Trial for LSALT Peptide

🚨 Arch Biopartners announced that St. Michael’s Hospital @unityhealthto.bsky.social received ethics approval to join the Phase II CS-AKI trial evaluating LSALT peptide.

🏥 4th Canadian site, 9th globally.

🔗 Read more (and share): www.archbiopartners.com/arch-biopart...

#LSALTpeptide #AKI #CSAKI

Predicting pediatric cardiac surgery-associated acute kidney injury using machine learning - Pediatric Nephrology Background Prediction of cardiac surgery-associated acute kidney injury (CS-AKI) in pediatric patients is crucial to improve outcomes and guide clinical decision-making. This study aimed to develop a ...

🔎 A Pediatric Nephrology study (@ped-neph.bsky.social link.springer.com/article/10.1007/s00467-023-06197-1) shows machine learning can help predict AKI in children after heart surgery. Arch’s trials are evaluating drugs to prevent AKI in high-risk patients.

🔬 archbiopartners.com/our-science

#CSAKI

Hemolysis Index and Cardiopulmonary Bypass Time as Predictors of Cardiac Surgery-associated Acute Kidney Injury: An Observational Cohort Study Acute kidney injury (AKI) is a common and serious complication of cardiac surgery, often linked to the use and duration of cardiopulmonary bypass (CPB). The Hemolysis Index (HI) has been proposed as a...

📚 Nov 2025 study in JCVA jcvaonline.com/article/S1053-0770(25)00632-9/fulltext In >1,000 cardiac surgery patients, elevated hemolysis index, and longer bypass time predicted AKI. Supports inflammation-targeted CS-AKI therapies.

🔬 archbiopartners.com/our-science/lsaltpeptide/

#CSAKI #LSALTpeptide

Models of sepsis-induced acute kidney injury Sepsis-induced acute kidney injury (S-AKI) is one of the most serious life-threatening complications of sepsis. The pathogenesis of S-AKI is complex a…

🧪 A Life Sciences review (www.sciencedirect.com/science/arti...) confirms that inflammation, vascular injury, and mitochondrial damage drive S-AKI.

These same mechanisms are also active in cardiac surgery-associated AKI (CS-AKI).

🔬 archbiopartners.com/our‑science/lsaltpeptide

#AKI #CSAKI #NephSky

Acute Kidney Injury: A Blocked Diagnosis Acute kidney injury (AKI) is a common medical condition that we encounter in our daily clinical practice. However, in certain cases, ascertaining the underlying cause of the AKI could be challenging a...

📚 An AKI case in @cureusmedical.bsky.social (doi.org/10.7759/cureus.88144) shows how difficult diagnosis can be without clear criteria.

Arch’s ongoing Phase II trial for CS-AKI uses KDIGO to guide consistent diagnosis.

🔬 archbiopartners.com/our-science/lsaltpeptide

#AKI #CSAKI #KDIGO #NephSky

November 5, 2025 - News Release Arch Biopartners Expands Phase II Cardiac Surgery-Associated AKI Trial to Include Royal Columbian Hospital in British Columbia

🚨 Arch Biopartners has announced that the @fraserhealth.ca Research Ethics Board has approved Royal Columbian Hospital to join its Phase II trial of LSALT peptide to prevent CS-AKI.

📖 Latest News at www.archbiopartners.com/investor-hub/

#AKI #CSAKI #KidneyCare #NephSky

Frontiers | Clinical characteristics and risk factors of cardiac surgery associated-acute kidney injury progressed to chronic kidney disease in adults: A retrospective, observational cohort study IntroductionTo retrospectively investigate the clinical characteristics and risk factors of cardiac surgery associated-acute kidney injury (CS-AKI) progresse...

📚 @frontiersin.bsky.social Cardiovasc. Med. (doi.org/10.3389/fcvm.2023.1108538) - 1 in 5 adults with CS-AKI develop CKD within 90 days.

Arch is a therapeutic biotech company supporting two Phase II AKI trials and a CKD platform.

🔬 archbiopartners.com/our-science

#CKD #CSAKI #LSALTpeptide #NephSky

Frontiers | Clinical practice guidelines for acute kidney injury: a systematic review of the methodological quality ObjectiveHospitalized patients, particularly those in the ICU, face a significant risk of acute kidney injury (AKI). Clinical practice guidelines (CPGs) that...

📚 A 2025 review confirms KDIGO 2012 as the leading AKI guideline (doi.org/10.3389/fmed.2025.1567359).

Arch Biopartners’ Phase II trial for CS‑AKI uses KDIGO to define AKI after cardiac surgery.

🔬 archbiopartners.com/our-science/metablok

#AKI #CSAKI #NephSky #ArchScience #LSALTpeptide

Infographic from Clinical Investigation, Volume 101, Issue 6, p1271-1281June 2022. Harmonization of epidemiology of acute kidney injury and acute kidney disease produces comparable findings across four geographic populations Sawhney, Simon et al. Kidney International, Volume 101, Issue 6, 1271 - 1281

📊 A 2022 study in Kidney International (doi.org/10.1016/j.kint.2022.02.033) showed consistent AKI incidence and outcomes across Canada, Denmark, and the UK using harmonized KDIGO definitions.

Supports the need for targeted kidney therapies.

🔬 archbiopartners.com/our-science

#AKI #CSAKI #NephSky

Urinary IL-18 is an early predictive biomarker of acute kidney injury after cardiac surgery Acute kidney injury (AKI) is a frequent complication of cardiopulmonary bypass (CPB). The lack of early biomarkers for AKI has impaired our ability to intervene in a timely manner. Urinary neutrophil ...

🧪 A 2006 Kidney Int. study showed urinary IL-18 rises early in AKI after cardiac surgery.

This helped shape AKI risk models. Arch is now sponsoring a Phase II CS-AKI trial with LSALT peptide.

🔬 archbiopartners.com/our-science

#AKI #CSAKI

Full article: www.kidney-international.org/article/S008...

Optimizing the Design and Analysis of Future AKI Trials : Journal of the American Society of Nephrology ical thresholds. Heterogeneity in the pathobiology, etiology, presentation, and clinical course of AKI remains a key challenge in successfully testing new approaches for AKI prevention and treatment. ...

🔍 A 2022 JASN consensus (doi.org/10.1681/asn.2021121605) calls for AKI trials focused on clear subtypes like CS-AKI, with better biomarkers and endpoints.

Arch is supporting two Phase II trials for CS-AKI and DI-AKI.

🔬 archbiopartners.com/our-science

#AKI #CSAKI #TrialRationale #ArchBiopartners

News release headline, clinical trial update from Arch Biopartners, August 6, 2025. Arch Biopartners Announces First Patient Successfully Dosed at Toronto General Hospital in Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury

Arch Biopartners’ CS-AKI Phase II clinical trial is now active at Toronto General Hospital, ranked Canada's #1 and #3 globally.

First patient dosed in the trial at this leading cardiac research hospital.

🔗 dub.sh/first-patien...

#ArchBiopartners #CSAKI #AKI #LSALTpeptide #clinicaltrials #ArchNews

Perioperative Acute Kidney Injury: An Under-Recognized... : Anesthesia & Analgesia ber of individuals with chronic comorbidities, particularly those with premorbid chronic kidney disease. Despite the acceptance of standardization in the definition of AKI, clinicians routinely underd...

🔬 2017 review in Anesth Analg (doi.org/10.1213/ane.0000000000002369) noted perioperative AKI as common but overlooked, underscoring the need for solutions.

Arch’s LSALT peptide is in Phase II to address this risk.

🌐 More: archbiopartners.com/our-science

#CSAKI #AKI #KidneyCare #ArchBiopartners

Validate User

📊 Even mild post-surgical AKI raises mortality, ICU time, and costs (NDT, 2008, academic.oup.com/ndt/article-...).

🔗 Arch is targeting CS-AKI in an ongoing, sponsor-led international Phase II trial: archbiopartners.com/our-science/metablok/#trial-history

#AKI #CSAKI #KidneyCare #LSALTpeptide

Acute Kidney Injury Is Associated With Increased Long-Term Mortality After Cardiothoracic Surgery | Circulation Background— Long-term survival after acute kidney injury (AKI) is poorly studied. We report the relationship between long-term mortality and AKI with small changes in serum creatinine during hospitali...

Friday Deep Dive — 2009 study in “Circulation” (doi.org/10.1161/CIRCULATIONAHA.108.800011) found cardiac surgery–associated AKI predicts higher long-term mortality, even years after discharge.
🔬 International CS-AKI Phase II Trial: archbiopartners.com/our-science
#CSAKI #KidneyCare #ArchScience

Our Science – Arch Biopartners

💰 2022 study in J Crit Care (doi.org/10.1016/j.jcrc.2021.12.011) found delayed RRT in CS-AKI = longer ICU stays and higher costs.

Arch’s science program is focused on preventing CS-AKI and improving patient outcomes.

🔬 archbiopartners.com/our-science/

#CSAKI #ArchScience #AKI #KidneyCare

Cardiac Surgery–Associated Acute Kidney Injury : Kidney360 [CSA-AKI]) on the basis of changes in serum creatinine and/or urine output. There are various preoperative, intraoperative, and postoperative risk factors for the development of CSA-AKI which should b...

📚 2024 review in Kidney360 (doi.org/10.34067/KID.0000000000000466) emphasizes the burden of CS-AKI, with inflammation and ischemia as central causes—and no approved treatments available.

🔬 Arch is focused on prevention: archbiopartners.com/our-science/

#CSAKI #AKI #KidneyCare #ArchScience

Cardiac and Vascular Surgery–Associated Acute Kidney Injury: The 20th International Consensus Conference of the ADQI (Acute Disease Quality Initiative) Group | Journal of the American Heart Associatio...

🫀 A 2018 international consensus led by ADQI (doi.org/10.1161/JAHA.118.008834) cites inflammation, IRI, and toxins as causes of AKI.

These drivers match the targets of Arch Biopartners’ clinical strategy.

📖 Learn more: archbiopartners.com/our-science

#CSAKI #AKI #TrialRationale #KidneyCare

Our Science – Arch Biopartners

🌐 Cardiac surgery demand exceeds global capacity 12-to-1 (June 2024 - doi.org/10.1016/j.atssr.2023.11.019).

As access grows, so does the burden of CS-AKI—and the need for prevention.

📖 Learn more: archbiopartners.com/our-science

#ArchBiopartners #CSAKI #TrialRationale #ArchScience #InvestorFAQ

Practice Variation in Cardiac Surgery and Acute Kidney Injury This cohort study assesses operating room practices for vasopressor infusions, inotrope infusions, red blood cell transfusions, and fluid volume administration and their association with postsurgical ...

🩺 A 2025 JAMA Network Open study (doi.org/10.1001/jamanetworkopen.2025.8342) finds CS-AKI rates vary widely—11.7% to 32.8%—driven by intraoperative practices.

🔔 How Arch is addressing AKI in cardiac surgery: archbiopartners.com/our-science

#CSAKI #AKI #ArchScience #TrialRationale #KidneyCare

(PDF) Combination of urinary biomarkers can predict cardiac surgery-associated acute kidney injury: a systematic review and meta-analysis PDF | Introduction Acute kidney injury (AKI) develops in 20–50% of patients undergoing cardiac surgery (CS). We aimed to assess the predictive value of... | Find, read and cite all the research you ne...

🧪 A recent meta-analysis supports the use of urinary biomarkers to predict AKI after cardiac surgery.
Findings align with Arch’s CS-AKI trial with LSALT peptide.

📖 Full study www.researchgate.net/publication/...

More at archbiopartners.com/our-science

#ArchBiopartners #CSAKI #AKI #TrialRationale

Arch Biopartners Announces Toronto General Hospital Ethics Board Approval to Join the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI) – Arch Biopartn...

🚨 (22 April 2025) Arch Biopartners announced that UHN-TGH (Toronto General Hospital) is prepared to begin recruiting subjects for the Phase II trial of LSALT peptide for CS-AKI.

📖 Full release at – dub.sh/arch-uhn-tgh...

#AKI #CSAKI #KidneyCare #LSALTpeptide #ArchBiopartners #DPEP1 #ArchNews

📢 Arch Biopartners’ May 2025 Corporate Presentation –Covers the CS-AKI and PONTiAK Phase II trials targeting inflammation- and toxin-related AKI.
📽️ Download the presentation and subscribe for updates at the Arch Investor Hub: www.archbiopartners.com/investor-hub/
#ArchBiopartners #CSAKI #InvestorFAQ